The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -69,461 | -87,911 |
| Depreciation and amortization | 21,033 | 42,135 |
| Premium deficiency reserve | -23,736 | -12,929 |
| Paid in-kind interest expense | 19,813 | - |
| Amortization of original issue discount and debt issuance costs | 10,981 | 402 |
| Equity-based compensation | 1,211 | 3,271 |
| Mark-to-market adjustment of stock warrants | 2,540 | -5,324 |
| Gain (loss) on disposition of property plant equipment, excluding oil and gas property and timber property | -340 | - |
| Gain on write off of contingent consideration | 0 | - |
| Health plan receivable | -11,439 | -27,803 |
| Clinic fees, insurance, and other receivable | -3,834 | 3,625 |
| Prepaid expenses and other current assets | -4,762 | 1,747 |
| Other long-term assets | -2,190 | 14,464 |
| Accounts payable, accrued expenses, and other current liabilities | 1,586 | 6,200 |
| Accrued payroll | 187 | -1,560 |
| Health plan settlements payable | 11,609 | -13,694 |
| Claims payable | -2,373 | 948 |
| Accrued interest | -12,653 | 10,619 |
| Operating lease liability | 1,286 | -223 |
| Net cash used in operating activities | -15,412 | -50,099 |
| Purchases of property and equipment | 119 | - |
| Proceeds from asset sale | 0 | 50 |
| Net cash (used in) provided by investing activities | -119 | 50 |
| Proceeds from long-term debt, net of original issue discount | 15,000 | 45,000 |
| Proceeds from short-term debt | 0 | 1,137 |
| Repayment of short-term and long-term debt | 341 | 682 |
| Payment of debt issuance costs | -7 | 181 |
| Proceeds from liability-classified warrants and private placement offering, net of offering costs paid | 0 | 0 |
| Deferred offering costs paid | 0 | 0 |
| Payment of tax withholdings upon settlement of restricted stock unit awards | 0 | 0 |
| Proceeds from at-the-market sales, net of offering costs paid | 0 | 0 |
| Net cash provided by financing activities | 14,666 | 45,274 |
| Net change in cash and restricted cash | -865 | -4,775 |
| Cash and cash equivalents at beginning of period | 44,102 | - |
| Cash and cash equivalents at end of period | 38,462 | - |
P3 Health Partners Inc. (PIIIW)
P3 Health Partners Inc. (PIIIW)